AstraZeneca pays high price to fill drugs chest with £700m CAT deal
AstraZeneca paid a hefty premium to take over Britain's biggest biotechnology firm, Cambridge Antibody Technology, in a £702m deal yesterday, in the latest attempt to fill its threadbare drugs pipeline.
CAT's chief executive, Peter Chambre, who is leaving, is in line for a windfall of up to £2.2m from his 29,100 shares and share options in various incentive schemes.
Shares in AstraZeneca, Europe's biggest drug maker, closed down 7p at 2,850p yesterday amid investor concerns about the cost, which was £100m higher than expected.
The Anglo-Swedish company already owns 19.2 per cent of CAT under a £75m research alliance signed in 2004 and will splash out £567m for the rest of the company after agreeing to pay 1,320p a share in cash. The price represents a 67 per cent premium to CAT's closing price on Friday. The loss-making biotech firm is a world leader in developing drugs from antibodies, the body's natural immune defences. The deal gives AstraZeneca a drug in Phase II clinical trials and another in Phase I.
AstraZeneca wants to make CAT its centre for developing biological drugs to treat cancer, nervous diseases and asthma, and will make unspecified payments to retain the company's 300 scientists in Cambridge. The market for antibody-based drugs is forecast to more than double by 2010 from $14bn (£7.5bn) in 2005.
John Patterson, AstraZeneca's executive director of development, said: "Up to one in four of our later-stage molecules by 2010 will be from a biologicals background, whereas previously we've had little or no capability."
Unlike some of its rivals, AstraZeneca has been slow in investing in biological medicines, a fast-growing market.
David Brennan, AstraZeneca's chief executive, reiterated his priority to replenish the pipeline of new medicines, and said the company would continue to look for acquisitions. That signals a determination to remain independent despite persistent speculation that it is a takeover target.
The group has spent £1.5bn, including the CAT deal, in the past six months buying in new drugs. But some critics say the deals are expensive and risky.
CAT joins other large British biotechs in selling up: Celltech was snapped up by Belgium's UCB two years ago while in 2002 Powderject sold out to Chiron, now part of the Swiss group Novartis.
- 1 Caitlyn Jenner car crash: Driver who died in collision sued by surviving passengers for $18.5m
- 2 Pictures show young Palestinian girl biting Israeli soldier trying to detain boy during West Bank protests
- 3 Watch the Supermoon live: How to see the brightest Moon of the year tonight
- 4 Blood Moon and Supermoon: September to bring brightest – and dimmest – full Moon of the year on same night
- 5 The 20 toughest job interview questions in the world
Caitlyn Jenner car crash: Driver who died in collision sued by surviving passengers for $18.5m
Pictures show young Palestinian girl biting Israeli soldier trying to detain boy during West Bank protests
Celebrity Big Brother 2015: Tila Tequila kicked off show after 'describing Hitler as a good man'
Watch the Supermoon live: How to see the brightest Moon of the year tonight
Hulk Hogan wants to be Donald Trump's running mate in the US Presidential election
Climate change: 2015 will be the hottest year on record 'by a mile', experts say
'Women only' train carriages: Jeremy Corbyn unveils radical move to tackle public harassment
Black holes are a passage to another universe, says Stephen Hawking
Iain Duncan Smith 'should resign over disability benefit death figures', says Jeremy Corbyn
Stock up on canned food for stock market crash, warns former Gordon Brown adviser
Labour leadership: Jeremy Corbyn voters most likely to believe 'world is controlled by a secretive elite'
iJobs Money & Business
£25000 - £30000 per annum: Recruitment Genius: From modest beginnings the comp...
£35000 - £40000 per annum: Recruitment Genius: From modest beginnings the comp...
£15000 - £65000 per annum: Recruitment Genius: This is an exciting opportunity...
£18000 - £20000 per annum: Recruitment Genius: This is a fantastic opportunity...